Fig. 3

Probability of melanoma-specific survival using combined expression profiles of all p53 isoforms. Kaplan–Meier plots of melanoma-specific survival in all melanomas based on composite biomarkers of p53 isoform expression segregated into high (H) and low (L) according to the median expression of each isoform. A. Cytoplasmic p53 isoform expression patterns HHHH (n = 14), HHHL (n = 1; not included); HHLH (n = 5), HHLL (n = 6), HLHH (n = 2, not included), HLHL (n = 3, not included), HLLH (n = 2, not included), HLLL (n = 7), LHHH (n = 5), LHHL (n = 3, not included), LHLH (n = 2, not included), LHLL (n = 4), LLHH (n = 3, not included), LLHL (n = 6), LLLH (n = 3, not included), LLLL (n = 13). B. Nuclear p53 isoform expression patterns HHHH (n = 12), HHHL (n = 5), HHLH (n = 5), HHLL (n = 6), HLHH (n = 3, not included), HLHL (n = 1, not included), HLLH (n = 2, not included), HLLL (n = 6), LHHH (n = 5), LHHL (n = 2, not included), LHLH (n = 2, not included), LHLL (n = 2, not included), LLJJ (n = 4), LLHL (n = 9), LLLH (n = 9), LLLL (n = 6). C. Combined cytoplasmic p53 isoform expression patterns. Left: HHLL (n = 6), others (n = 67); center: HHLL, LHLH, and LLHL (n = 12), others (n = 61); right: HHLL, LHLH, LLHL, HLLH, and HHHL (n = 20), others (n = 53). D. Combined nuclear p53 expression patterns. Left: HHHL (n = 5), others (n = 62); center: HHHL and HHHL (n = 17), others (n = 50); right: HHHL, HHHH, LLLL, LLHL, and LLLH (n = 41), others (n = 26). Significance determined by Log-rank (Mantel-Cox) tests. ns not significant; *—p < 0.05; **—p < 0.01; ***—p < 0.001. p-values ≥ 0.0091 did not pass multiple comparison testing (applicable to HHHL vs LLHL, HHHL vs LLLL, HHHL vs LLLH, LLHL vs LLLH, HHHL + HHHH + LLLL + LLHL + LLLH vs all others, HHLL vs LLLL, HHLL + LHLH + LLHL + HLLH + HHHL vs all others, HHHL vs HLLL, HLLL vs LHHL, HHLL vs HLLL, HHLH vs LLHL, HHHH vs LLLL, HHLH, HLLL, LHLL vs LLLL, HHHH vs HLLL, HHLL vs LLHL, LHHL vs LLHL)